Longevity Clinics: What You Are Actually Buying, and What the Trials Actually Show

The longevity clinic used to be a fringe proposition — a clinic selling growth hormone to people who had read about it on a message board. It is now a retail category with a pricing ladder. At the bottom sit remote blood-panel subscriptions: roughly $199 to $365 a year for a hundred or more lab tests, a dashboard, and algorithmic “protocols.” In the middle sits imaging: a full-body MRI package advertised around $3,999. Above that sit the executive assessments — genome sequencing, whole-body and brain MRI, echocardiography, DEXA and a coronary calcium score bundled at $8,000 a year, with concierge tiers at $12,000 and $19,000. At the top, in a category of one, sits a self-experimenter who has reported spending about $2 million a year on his own program.

The pitch is that aging itself is a treatable condition, and that the clinic is where you go to treat it. The honest version is more layered. Some of what these businesses sell is ordinary preventive medicine made luxurious. Some is measurement without a demonstrated payoff. And some is experimental therapy sold with a confidence the underlying trials have not earned. A fair review has to keep those three shelves separate, because a legitimate test result does not validate the whole bundle.

What holds up

The medical core is real. Blood panels that catch diabetes, kidney disease and dyslipidemia; coronary calcium scoring, which has decades of prognostic evidence behind it; fitness and body-composition testing; and the unglamorous counseling about sleep, exercise and not smoking that, in large cohort studies, tracks with longer life better than any boutique intervention. A person who has never had basic screening and buys it here is purchasing something genuinely useful. That is a lower bar than the marketing claims, but it is a real one.

The research field the clinics borrow from — geroscience — is also real, and in places genuinely exciting. Caloric restriction, the one intervention with the longest human record, produced a randomized result worth taking seriously: in the CALERIE trial’s DNA-methylation analysis, published in Nature Aging in 2023, two years of caloric restriction slowed one pace-of-aging measure (DunedinPACE) in healthy adults. That is a genuine biomarker signal from a rigorous trial. It is also, precisely, a biomarker signal — CALERIE did not show that its participants lived longer, and it did not move every clock: PhenoAge and GrimAge did not change significantly. Even the best-supported intervention in the field produces clock-specific results that researchers themselves describe carefully.

What doesn’t hold up

Start with the epigenetic clock itself, the test many clinics sell as a personal age with a decimal point. A lower number is a laboratory output, not a demonstration that the customer became physiologically younger, will avoid disease, or gained a day of life. The trials show why this matters. The most-cited “age reversal” result, the 2019 TRIIM pilot, reported mean epigenetic age about 1.5 years below baseline in nine men treated with growth hormone, metformin and DHEA — an uncontrolled study with no comparator, a sample smaller than most clinic waiting rooms, and three interventions whose individual contributions cannot be separated. It is cited in clinic marketing as if it were a proof of concept for reversal. It is a hypothesis generator.

The off-label drug story repeats the pattern with more money involved. Rapamycin, the mTOR inhibitor with strong lifespan data in mice, finally got a placebo-controlled human trial: PEARL, a 48-week randomized study published in 2025, tested weekly compounded rapamycin and missed its primary endpoint — visceral adiposity did not change significantly (p=0.942). Some secondary outcomes, including lean tissue in one dose group, moved favorably; the authors noted adverse events were similar to placebo over the study period. That is a real trial and a null primary result — not the proof of human lifespan extension the prescription-it-to-yourself market implies. Metformin’s flagship human test, the TAME trial, remains a designed rather than completed program; metformin’s benefits in diabetes have never been shown to extend life in people without it.

A lower number on a biological clock is a laboratory output. Whether it means anything for how long you live is a question the field has not yet answered for any intervention.

Hormone “optimization” deserves its own caution, because it borrows credibility from a legitimate indication. Testosterone replacement for diagnosed hypogonadism is standard medicine; the TRAVERSE trial, which followed 5,246 men with low testosterone and cardiovascular risk, found testosterone gel noninferior to placebo for major cardiac events — reassuring on safety, at the cost of more atrial fibrillation, acute kidney injury and pulmonary embolism in the treated group, and no claim anywhere in the trial about extending life. Nothing in TRAVERSE supports prescribing testosterone to a healthy 52-year-old whose levels are merely “suboptimal,” which is precisely the customer most hormone clinics are built around.

The diagnostic upsell has its own regulator problem. Whole-body MRI finds abnormalities — that is what it is for — but the American College of Radiology’s 2023 statement found insufficient evidence to recommend screening asymptomatic people at average risk, noted no documented evidence of life prolongation or cost-effectiveness, and warned specifically about nonspecific findings leading to unnecessary follow-up procedures. A scan that finds more things is not a scan that prevents more deaths; the gap between those two sentences is where incidentaloma anxiety, repeated imaging and downstream interventions live.

The injectables tier carries the starkest warnings of all, because they come from the FDA rather than from skeptics. The agency has reported severe reactions — chills, shaking, vomiting, fatigue — after NAD+ infusions, warned about unsuitable food-grade ingredients and endotoxin contamination in compounded batches, and flagged significant potential safety risks for several peptide products sold through compounding pharmacies, including BPC-157. None of these is an approved drug for an anti-aging indication; availability through a clinic is not approval. The FDA’s hyperbaric guidance makes the same point for the chamber: legitimate for defined medical indications, marketed widely for uses the evidence does not support.

The industry’s own scientists are saying versions of this. A 2025 commentary by longevity researcher Marco Demaria, titled “Longevity clinics: between promise and peril,” describes the gap between promising laboratory geroscience and premature commercial translation — including the risk of costly experimentation and outright pseudoscience moving in under the same roof. It is not a takedown of any business; it is a warning from inside the field that the translation outran the data.

What a reader should take from this

The longevity clinic tier list, by evidence: blood panels and guideline preventive care sit on solid ground. Coronary calcium scoring has real prognostic value in the right patients, ordered with a clinician who will act on it. Everything above that line — repeat epigenetic clocks as a personal scoreboard, whole-body MRI at average risk, NAD+ drips, peptide injections, off-label rapamycin, hormone titration in the unimpaired — is currently selling measurement or hope at prices the trials have not validated, in some cases against FDA warnings.

That does not make the customers fools or the field dead. CALERIE, PEARL and TRAVERSE are exactly how the questions get answered, and some answers will eventually be positive. But a person buying today is buying early access to unfinished science at boutique prices, and the honest marketing would say so. The most defensible purchase in the entire sector remains the one that costs the least and comes with the least branding: the standard bloodwork your physician would have ordered anyway, interpreted by someone who will still be seeing you next year.

This article is general information, not medical advice. See our Editorial Standards.